These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 23537510)

  • 1. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
    Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
    J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.
    Christadoss P; Tüzün E; Li J; Saini SS; Yang H
    Ann N Y Acad Sci; 2008; 1132():210-9. PubMed ID: 18567870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting complement system to treat myasthenia gravis.
    Huda R; Tüzün E; Christadoss P
    Rev Neurosci; 2014; 25(4):575-83. PubMed ID: 24731953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
    Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
    J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.
    Huda R; Strait RT; Tüzün E; Finkelman FD; Christadoss P
    J Neuroimmunol; 2015 Apr; 281():68-72. PubMed ID: 25867470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice.
    Theissen L; Schroeter CB; Huntemann N; Räuber S; Dobelmann V; Cengiz D; Herrmann A; Koch-Hölsken K; Gerdes N; Hu H; Mourikis P; Polzin A; Kelm M; Hartung HP; Meuth SG; Nelke C; Ruck T
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement and cytokine based therapeutic strategies in myasthenia gravis.
    Tüzün E; Huda R; Christadoss P
    J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
    Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
    Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of complement in experimental autoimmune myasthenia gravis.
    Kusner LL; Kaminski HJ
    Ann N Y Acad Sci; 2012 Dec; 1274(1):127-32. PubMed ID: 23252907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell surface complement regulators moderate experimental myasthenia gravis pathology.
    Kusner LL; Halperin JA; Kaminski HJ
    Muscle Nerve; 2013 Jan; 47(1):33-40. PubMed ID: 23042232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
    Biesecker G; Gomez CM
    J Immunol; 1989 Apr; 142(8):2654-9. PubMed ID: 2703710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
    J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
    Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
    Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting classical complement pathway to treat complement mediated autoimmune diseases.
    Tüzün E; Li J; Saini SS; Yang H; Christadoss P
    Adv Exp Med Biol; 2008; 632():265-72. PubMed ID: 19025128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.